| Bioactivity | Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone proteasome inhibitor with IC50s of 36 and 82 nM for proteasome (β5) and immunoproteasome (LMP7), respectively. Oprozomib (ONX 0912) induces apoptosis in MM cells[1]. | ||||||||||||
| Invitro | Oprozomib inhibits 20S chymotrypsin-like (CT-L) with an IC50 of 55 ± 19 nM. Oprozomib inhibits human leukemia Molt-4 cells CT-L with an IC50 of 66 nM[1].Oprozomib (ONX 0912; 1-1000 nM; 48 hours) significantly decreases the viability of human multiple myeloma (MM) cell lines[2].The anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP[2]. Cell Viability Assay[2] Cell Line: | ||||||||||||
| Name | Oprozomib | ||||||||||||
| CAS | 935888-69-0 | ||||||||||||
| Formula | C25H32N4O7S | ||||||||||||
| Molar Mass | 532.61 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Oprozomib
CAS: 935888-69-0 F: C25H32N4O7S W: 532.61
Oprozomib (PR-047) is an orally bioavailable and selective peptide epoxyketone proteasome inhibitor with IC50s of 36 and
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.